Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CONCETTA M FORCHETTI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1184656852
CMS profile
189389
Location
ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$565.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $565.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $565.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CONCETTA M FORCHETTI

NPI 1184656852 · CMS profile ID 189389

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184656852?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184656852?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184656852?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1184656852?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $565.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $565.0012/17/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737255071 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,113.42 4
PY2020 $565.00 1
PY2021 $38,624.37 33
PY2022 $15,350.00 6
PY2023 $16,660.79 32
PY2024 $39,378.02 40
PY2025 $50,287.88 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $908,463.90 81
PY2024 Principal investigator $630,831.36 79
PY2023 Recipient $591.95 2
PY2023 Principal investigator $1,785,779.63 92
PY2022 Recipient $10,066.00 2
PY2022 Principal investigator $1,648,640.76 51
PY2021 Recipient $1,310.44 2
PY2021 Principal investigator $1,377,364.84 65
PY2020 Recipient $2,195.35 2
PY2020 Principal investigator $1,008,121.30 81
PY2019 Recipient $294.51 1
PY2019 Principal investigator $1,007,212.44 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $34.76 12/31/2021 Non-covered Recipient Entity
AMITA HEALTH ALEXIAN BROTHERS NEUROSCIENCES INSTITUTE CLINICAL RESEARCH
A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer s Disease Dementia No dispute reported 06/30/2026 848742325
Principal investigator 1 Merck Sharp & Dohme Corporation $62.26 12/31/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 848764677
Principal investigator 1 Genentech, Inc. $2,889.00 12/16/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935213
Principal investigator 1 Genentech, Inc. $4,815.00 12/08/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935207
Principal investigator 1 Genentech, Inc. $14,809.32 11/16/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935201
Principal investigator 1 Genentech, Inc. $6,741.00 10/18/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935195
Recipient Eli Lilly and Company $1,013.90 10/08/2021 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819443717
Principal investigator 1 Eli Lilly and Company $12.02 09/20/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819450511
Principal investigator 1 Genentech, Inc. $600.00 09/13/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935271
Principal investigator 1 Genentech, Inc. $3,852.00 09/02/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935189
Principal investigator 1 Eli Lilly and Company $43.80 08/26/2021 Non-covered Recipient Entity
YALE UNIVERSITY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819470671
Principal investigator 1 Genentech, Inc. $50.00 08/24/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935183
Principal investigator 1 Genentech, Inc. $500.00 08/19/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935177
Principal investigator 1 Genentech, Inc. $46,317.90 08/17/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935265
Principal investigator 1 Genentech, Inc. $16,609.68 08/12/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935171
Principal investigator 1 Genentech, Inc. $200.00 08/10/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935159
Principal investigator 1 Genentech, Inc. $50.00 08/10/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935165
Principal investigator 1 Janssen Research & Development, LLC $1,370.00 07/19/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 787608381
Principal investigator 1 Genentech, Inc. $300.00 07/16/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935153
Principal investigator 1 Genentech, Inc. $100.00 07/14/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935147
Principal investigator 1 Eli Lilly and Company $1,157.00 07/06/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819451281
Principal investigator 1 Genentech, Inc. $100.00 07/02/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935142
Principal investigator 1 Janssen Research & Development, LLC $600.00 07/01/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 787608363
Principal investigator 1 Janssen Research & Development, LLC $300.00 07/01/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 787608371
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,691.00 07/01/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK OFFICE OF CLINICAL RESEARCH GERALYN CHERESO
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF TWO DOSES OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF AD No dispute reported 06/30/2026 800619955
Principal investigator 1 Genentech, Inc. $101.00 06/23/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935105
Principal investigator 1 Genentech, Inc. $101.00 06/23/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935111
Principal investigator 1 Genentech, Inc. $101.00 06/23/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935117
Principal investigator 1 Genentech, Inc. $101.00 06/23/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935123
Principal investigator 1 Genentech, Inc. $101.00 06/23/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935129
Principal investigator 1 Genentech, Inc. $101.00 06/23/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935137
Principal investigator 1 Genentech, Inc. $7,555.50 06/14/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935099
Principal investigator 1 Genentech, Inc. $50.00 06/04/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935095
Principal investigator 1 Genentech, Inc. $50.00 06/01/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935089
Principal investigator 1 Eli Lilly and Company $311.12 05/21/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819451277
Principal investigator 1 Genentech, Inc. $200.00 05/21/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935083
Principal investigator 1 Genentech, Inc. $11,244.42 05/12/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935079
Principal investigator 1 Eli Lilly and Company $305,125.00 05/03/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819450231
Principal investigator 1 Eli Lilly and Company $50.00 04/30/2021 Non-covered Recipient Entity
SIERRA CLINICAL RESEARCH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819463795
Principal investigator 1 Eli Lilly and Company $571.25 04/30/2021 Non-covered Recipient Entity
STEVEN A DAVIS M D
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819469367
Principal investigator 1 Genentech, Inc. $3,757.50 04/19/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935259
Principal investigator 1 Genentech, Inc. $4,659.30 04/15/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935073
Principal investigator 1 Genentech, Inc. $303.00 04/12/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935069
Principal investigator 1 Genentech, Inc. $6,236.46 03/16/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935063
Principal investigator 1 Genentech, Inc. $111.87 03/01/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935253
Principal investigator 1 Eli Lilly and Company $56,309.30 02/23/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819450513
Principal investigator 1 Genentech, Inc. $1,249.00 02/22/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935247
Principal investigator 1 Genentech, Inc. $21,702.60 02/17/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935057
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 02/15/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 787608337
Principal investigator 1 Janssen Research & Development, LLC $8,500.00 02/15/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 787608347
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 02/15/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 787608355
Principal investigator 1 Genentech, Inc. $1,249.00 02/04/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935242
Recipient Eli Lilly and Company $296.54 01/29/2021 Covered Recipient Physician ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819443847
Principal investigator 1 Eli Lilly and Company $462.00 01/29/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER - NEUROSCIENCE RESEARCH INSTITUTE
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819451287
Principal investigator 1 Eli Lilly and Company $1,010.36 01/26/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 819450585
Principal investigator 1 Eli Lilly and Company $10,227.50 01/26/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819450685
Principal investigator 1 Genentech, Inc. $5,586.00 01/13/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935047
Principal investigator 1 Genentech, Inc. $4,545.00 01/13/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935051
Principal investigator 1 Genentech, Inc. $4,208.40 01/12/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935231
Principal investigator 1 Genentech, Inc. $500.00 01/12/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935237
Principal investigator 1 Genentech, Inc. $38.00 01/08/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935031
Principal investigator 1 Genentech, Inc. $101.00 01/08/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935035
Principal investigator 1 Genentech, Inc. $100.00 01/08/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 835935041
Principal investigator 1 Genentech, Inc. $577.00 01/08/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935225
Principal investigator 1 Genentech, Inc. $150.00 01/06/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 835935219
Principal investigator 1 Biogen, Inc. $811,163.52 01/01/2021 Non-covered Recipient Entity
Alexian Brothers Health System
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 829004321
Principal investigator 1 Eli Lilly and Company $150.00 01/01/2021 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER - NEUROSCIENCE RESEARCH INSTITUTE
ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 819450587